Eli Lilly recorded sales of $408 million in the first full year in the U.S. for its eczema treatment Evgris, which was launched in 2025. Now, after positive results in a Phase 3 trial of an IL-13 inhibitor, an Indianapolis drug company is poised to offer the drug to a younger group of patients.
The study, which included 363 patients ages 6 months to 18 years with moderate to severe atopic dermatitis, met key secondary endpoints by reducing disease symptoms while providing skin clearance and itch relief at 16 weeks, Lilly reported Monday. Participants received either a placebo or a weight-based dose of Ebglyss and topical steroids starting 2 weeks before randomization and continuing throughout the study.
Lilly said the trial met its primary endpoint, with 63% of patients receiving Evglis achieving significant skin improvement compared to 22% of patients receiving placebo. The Eczema Area Severity Index (EASI) was used as a measurement tool, and a 75% improvement from baseline was considered “meaningful.” As a secondary measure, 39% of patients receiving Ebglyss achieved a 90% improvement in the EASI index compared to 11% of patients receiving placebo.
As measured using the IGA (Investigator Global Assessment) index, a clinician rating scale from 0 (clear) to 4 (severe), Ebglyss’ success rate was 44%, with an IGA grade of 0 or 1 (nearly clear), compared with 15% of patients who met criteria on placebo.
Additionally, 35% of patients who received Ebglyss had a 4-point improvement in their pruritus (itching) symptoms compared to 6% of patients who received a placebo.
Lilly said it plans to submit these data to U.S. and global regulatory authorities for potential label updates.
Atopic dermatitis is more common in children than adults, affecting approximately 9.6 million children in the United States, with approximately one-third having moderate to severe disease.
“Children with moderate to severe atopic dermatitis often endure unrelenting skin redness, itching, and discomfort, which can interfere with play, school, and daily life for patients and their caregivers,” Adrian Brown, Lilly’s president of immunology, said in a release. “Evgris is already changing possibilities for adults and adolescents, delivering durable results that reduce relapse for patients with the option of monthly maintenance dosing.”
The FDA approved the approval of Ebglyss in September 2024 for patients with moderate to severe atopic dermatitis. This consent is for adults and children 12 years of age and older who weigh 88 pounds or more. Lilly acquired the treatment when it acquired California-based Dermira for $1.1 billion.
Almirall, which is commercializing the treatment in Europe, reported sales of Evgris in 2025 of 111 million euros ($125 million). In indications, Lilly and Almiral compete with Regeneron and Sanoifi’s strong IL-4 and IL-13 manufacturer Dupixent, which is already approved for children over 6 months of age, and Leo Pharma’s IL-13 Advry.
